The Promonitor® product portfolio is manufactured by Grifols and distributed by Aidian. Promonitor® biological drug monitoring tests offer key information about drug bioavailability and immunogenicity in patients prescribed with biological therapy for the treatment of chronic inflammatory diseases and other indications.
Promonitor® ELISA tests allow determination of biologic drug concentration and anti-drug antibody level in serum. The following biological treatments can be tested: infliximab, adalimumab, etanercept, rituximab, golimumab, vedolizumab and ustekinumab.
Promonitor® Quick ANTI-IFX, IFX and ADL Real Point-of-Care tests are available to facilitate immediate decisions for treatment management of patients treated with infliximab and adalimumab.